Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn’s disease: Systematic reviews and economic modelling

Health Technology Assessment

Volumn 20, Issue 83, 2016, Pages 1-288

  Freeman, Karoline ^a   Connock, Martin ^a   Auguste, Peter ^a   Taylor Phillips, Sian ^a   Mistry, Hema ^a   Shyangdan, Deepson ^a   Court, Rachel ^a   Arasaradnam, Ramesh ^b   Sutcliffe, Paul ^a   Clarke, Aileen ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; GASTROINTESTINAL AGENT; TUMOR NECROSIS FACTOR;

ALGORITHM; ALLERGIC REACTION; ARTHRALGIA; ARTICLE; ASSAY; BACTERIAL INFECTION; CHILL; CLINICAL EFFECTIVENESS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DEMYELINATION; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE INTENSIFICATION; DRUG MONITORING; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; ECONOMIC MODEL; ECZEMA; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FACE EDEMA; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEVER; FOOT EDEMA; HAND EDEMA; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEPATITIS; HOMOGENOUS MOBILITY SHIFT ASSAY; HUMAN; INFUSION RELATED REACTION; INJECTION SITE CONTUSION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INTERMETHOD COMPARISON; LEUKEMIA; LUPUS LIKE SYNDROME; LUPUS VULGARIS; LYMPHOMA; MEASUREMENT ACCURACY; MINIMUM PLASMA CONCENTRATION; MYALGIA; PNEUMONIA; PREDICTIVE VALUE; PSORIASIS; QUALITY ADJUSTED LIFE YEAR; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; RELAPSE; REMISSION; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SKIN CANCER; SKIN DEFECT; SKIN MANIFESTATION; SKIN ULCER; SYSTEMATIC REVIEW; THORAX PAIN; TUBERCULOSIS; URTICARIA; VIRUS INFECTION; ANTAGONISTS AND INHIBITORS; COST BENEFIT ANALYSIS; ECONOMICS; GERMANY; IMMUNOLOGY; MARKOV CHAIN; META ANALYSIS; PROCEDURES; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ADALIMUMAB; ALGORITHMS; COST-BENEFIT ANALYSIS; CROHN DISEASE; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; GASTROINTESTINAL AGENTS; GERMANY; HUMANS; INFLIXIMAB; MARKOV CHAINS; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85041856540     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta20830     Document Type: Article

References (185)

1. Merlin T, Lehman S, Hiller J, Ryan P. The ‘linked evidence approach’ to assess medical tests: a critical analysis. Int J Technol Assess Health Care 2013; 29: 343-50. http://dx.doi.org/10.1017/S0266462313000287
2. NICE. Crohn’s Disease: Management in Adults, Children and Young People. Clinical guideline 152. London: NICE; 2012. URL: www.nice.org.uk/guidance/cg152 (accessed 6 October 2014).
3. Clark W, Raftery J, Song F, Barton P, Cummins C, Fry-Smith A, et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn’s disease. Health Technol Assess 2003; 7(3). http://dx.doi.org/10.3310/hta7030
4. NHS Choices. Crohn’s Disease. NHS; 2013. URL: www.nhs.uk/Conditions/Crohns-disease/Pages/ Introduction.aspx (accessed 6 October 2014).
5. Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn’s disease. Health Technol Assess 2011; 15(6). http://dx.doi.org/ 10.3310/hta15060
6. NICE. Infliximab (Review) and Adalimumab for the Treatment of Crohn’s Disease. Technology appraisal 187. London: NICE; 2010. URL: www.nice.org.uk/guidance/TA187 (accessed 6 October 2014).
7. Hanauer SB, Sandborn W. Management of Crohn’s disease in adults. Am J Gastroenterol 2001; 96: 635-43. http://dx.doi.org/10.1111/j.1572-0241.2001.03671.x
8. Jenkins HR. Inflammatory bowel disease. Arch Dis Child 2001; 85: 435-7. http://dx.doi.org/10.1136/adc.85.5.435
9. Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A. Review article: Crohn’s disease: monitoring disease activity. Aliment Pharmacol Ther 2003; 17(Suppl. 2): 11-17. http://dx.doi.org/10.1046/j.1365-2036.17.s2.17.x
10. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 2007; 132: 863-73. http://dx.doi.org/10.1053/j.gastro.2006.12.003
11. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006; 55: 426-31. http://dx.doi.org/10.1136/gut.2005.069476
12. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, Modigliani R, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology 2002; 122: 512-30. http://dx.doi.org/10.1053/gast.2002.31072
13. Irvine EJ. Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995; 20: 27-32. http://dx.doi.org/10.1097/00004836-199501000-00008
14. Allez M, Karmiris K, Louis E, Van Assche G, Ben-Horin S, Klein A, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4: 355-66. http://dx.doi.org/10.1016/j.crohns.2010.04.004
15. Freeman K, Connock M, Mistry H, Taylor-Phillips S, Court R, Tsertsvadze A, et al. Crohn’s Disease: Tests for Therapeutic Monitoring of TNF Inhibitors (LISA-TRACKER ELISA kits, TNFα-Blocker ELISA kits, and Promonitor ELISA kits): Final Protocol. London: NICE; 2014. URL: www.nice.org.uk/guidance/gid-dt24/documents/crohns-disease-tests-for-therapeutic-monitoring-of-tnf-inhibitorslisatracker-elisa-kits-tnfablocker-elisa-kits-and-promonitor-elisa-kits-final-protocol2 (accessed 21 April 2015).
16. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol 2009; 104: 465-83. http://dx.doi.org/10.1038/ajg.2008.168
17. Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 2010; 4: 28-62. http://dx.doi.org/10.1016/j.crohns.2009.12.002
18. Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. URL: www.medicinescomplete.com (accessed 6 October 2014).
19. Joint Formulary Committee. British National Formulary for Children (online) London: BMJ Group and Pharmaceutical Press. URL: www.medicinescomplete.com (accessed 6 October 2014).
20. Gregor JC, McDonald JW, Klar N, Wall R, Atkinson K, Lamba B, et al. An evaluation of utility measurement in Crohn’s disease. Inflamm Bowel Dis 1997; 3: 265-76. http://dx.doi.org/10.1002/ibd.3780030405
21. Cohen RD. The quality of life in patients with Crohn’s disease. Aliment Pharmacol Ther 2002; 16: 1603-9. http://dx.doi.org/10.1046/j.1365-2036.2002.01323.x
22. IBD Standards Group. Standards for the Healthcare of People who have Inflammatory Bowel Disease (IBD): 2013 Update. IBD Standards; 2013. URL: www.ibdstandards.org.uk/uploaded_files/IBDstandards.pdf (accessed 25 February 2015).
23. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53: 1471-8. http://dx.doi.org/10.1136/gut.2004.041616
24. Jewell DP, Satsangi J, Lobo A, Probert C, Forbes A, Ghosh S, et al. Infliximab use in Crohn’s disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005; 17: 1047-52. http://dx.doi.org/10.1097/00042737-200510000-00007
25. Sprakes MB, Ford AC, Suares NC, Warren L, Greer D, Donnellan CF, et al. Costs of care for Crohn’s disease following the introduction of infliximab: a single-centre UK experience. Aliment Pharmacol Ther 2010; 32: 1357-63. http://dx.doi.org/10.1111/j.1365-2036.2010.04482.x
26. Buchanan J, Wordsworth S, Ahmad T, Perrin A, Vermeire S, Sans M, et al. Managing the long term care of inflammatory bowel disease patients: the cost to European health care providers. J Crohns Colitis 2011; 5: 301-16. http://dx.doi.org/10.1016/j.crohns.2011.02.005
27. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9. http://dx.doi.org/10.1016/S0140-6736(02)08512-4
28. Sands BE, Blank MA, Patel K, van Deventer SJ, ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004; 2: 912-20. http://dx.doi.org/10.1016/S1542-3565(04)00414-8
29. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. http://dx.doi.org/10.1053/j.gastro.2006.11.041
30. Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol 2014; 11: 243-55. http://dx.doi.org/10.1038/nrgastro.2013.253
31. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35. http://dx.doi.org/10.1056/NEJM199710093371502
32. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33. http://dx.doi.org/10.1053/j.gastro.2005.11.030
33. de Boer N, Lowenberg M, Hoentjen F. Management of Crohn’s disease in poor responders to adalimumab. Clin Exp Gastroenterol 2014; 7: 83-92.
34. Bendtzen K. Anti-TNF-alpha biotherapies: perspectives for evidence-based personalized medicine. Immunotherapy 2012; 4: 1167-79. http://dx.doi.org/10.2217/imt.12.114
35. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol 2009; 104: 760-7. http://dx.doi.org/10.1038/ajg.2008.88
36. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol 2011; 106: 674-84. http://dx.doi.org/10.1038/ajg.2011.60
37. Carrillo-Ramos MJ, Duarte-Chang C, Maldonado-Perez B, Beltran-Castano R, Castro-Laria L, Arguelles-Arias F, et al. Adalimumab or infliximab for the treatment of inflammatory bowel disease patients: which is more effective? Gastroenterology 2014; 146: S-196. http://dx.doi.org/10.1016/S0016-5085(14)60690-9
38. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol 2006; 4: 1248-54. http://dx.doi.org/10.1016/j.cgh.2006.06.025
39. Cassinotti A, Travis S. Why don’t we just measure infliximab drug levels in IBD? Pract Gastroenterol 2010; 34: 11-20.
40. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004; 2: 542-53. http://dx.doi.org/10.1016/S1542-3565(04)00238-1
41. Ungar B, Kopylov U, Yavzori M, Fudim E, Picard O, Lahat A, et al. Predictors of formation of antibodies to infliximab (ATI) and secondary loss of response in IBD patients treated with infliximab. J Crohns Colitis 2014; 8: S45. http://dx.doi.org/10.1016/S1873-9946(14)60087-8
42. Barry D, Bloomfeld RS. The prevalence of human antichimeric antibodies in patients on infliximab increases with age. Gastroenterology 2012; 142: S-387. http://dx.doi.org/10.1016/s0016-5085(12)61466-8
43. Baert F, Noman M, Vermeire S, Van Assche G, D’ Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003; 348: 601-8. http://dx.doi.org/10.1056/NEJMoa020888
44. Khanna R, Sattin BD, Afif W, Benchimol EI, Bernard EJ, Bitton A, et al. Review article: a clinician’s guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38: 447-59. http://dx.doi.org/10.1111/apt.12407
45. Vermeire S, Noman M, Van Assche G, Baert F, D’Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut 2007; 56: 1226-31. http://dx.doi.org/10.1136/gut.2006.099978
46. Vande Casteele N, Cuypers L, Singh S, Hauenstein S, Ohrmund L, Chuang E, et al. Transient versus sustained antibodies to infliximab: possibility to overcome low titer antibody responses by dose optimisation. J Crohns Colitis 2012; 6: S110. http://dx.doi.org/10.1016/S1873-9946(12)60273-6
47. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn’s disease. Am J Gastroenterol 2008; 103: 944-8. http://dx.doi.org/10.1111/j.1572-0241.2007.01638.x
48. Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology 2009; 137: 1628-40. http://dx.doi.org/10.1053/j.gastro.2009.07.062
49. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013; 72: 1947-55. http://dx.doi.org/10.1136/annrheumdis-2012-202220
50. Gils A, Vande Casteele N, Poppe R, Van de Wouwer M, Compernolle G, Peeters M, et al. Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization. Ther Drug Monit 2014; 36: 669-73. http://dx.doi.org/10.1097/FTD.0000000000000074
51. van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 2015; 74: 311-14. http://dx.doi.org/10.1136/annrheumdis-2014-206237
52. Steenholdt C, Palarasah Y, Bendtzen K, Teisner A, Brynskov J, Teisner B, et al. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37: 1172-83. http://dx.doi.org/10.1111/apt.12330
53. Van Assche G, Magdelaine-Beuzelin C, D’Haens G, Baert F, Noman M, Vermeire S, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-8. http://dx.doi.org/10.1053/j.gastro.2008.03.004
54. Feagan BG, McDonald JW, Panaccione R, Enns RA, Bernstein CN, Ponich TP, et al. Methotrexate for the prevention of antibodies to infliximab in patients with Crohn’s disease. Gastroenterology 2010; 138: S167-8. http://dx.doi.org/10.1016/S0016-5085(10)60767-6
55. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362: 1383-95. http://dx.doi.org/10.1056/NEJMoa0904492
56. Afif W, Loftus EV, Faubion WA Jr, Kane SV, Bruining DH, Hanson KA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1133-9. http://dx.doi.org/10.1038/ajg.2010.9
57. Roblin X, Rinaudo M, Del Tedesco E, Phelip JM, Genin C, Peyrin-Biroulet L, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol 2014; 109: 1250-6. http://dx.doi.org/10.1038/ajg.2014.146
58. Paul S, Del Tedesco E, Marotte H, Rinaudo-Gaujous M, Moreau A, Phelip JM, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2013; 19: 2568-76. http://dx.doi.org/10.1097/MIB.0b013e3182a77b41
59. Pariente B, Pineton de Chambrun G, Krzysiek R, Desroches M, Louis G, De Cassan C, et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 1199-206. http://dx.doi.org/10.1002/ibd.21839
60. Steenholdt C. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn’s disease. Dan Med J 2013; 60: B4616.
61. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther 2011; 33: 987-95. http://dx.doi.org/10.1111/j.1365-2036.2011.04612.x
62. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn’s disease: a critical systematic review. Inflamm Bowel Dis 2009; 15: 1264-75. http://dx.doi.org/10.1002/ibd.20899
63. Lee LY, Sanderson JD, Irving PM. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis. Eur J Gastroenterol Hepatol 2012; 24: 1078-85. http://dx.doi.org/10.1097/MEG.0b013e32835558cf
64. Chaparro M, Guerra I, Munoz-Linares P, Gisbert JP. Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 971-86. http://dx.doi.org/10.1111/j.1365-2036.2012.05057.x
65. Vande Casteele N, Gils A, Ballet V, Compernolle G, Peeters M, Van Steen K, et al. Randomised controlled trial of drug level versus clinically based dosing of infliximab maintenance therapy in IBD: final results of the TAXIT Study (OP001). United Europ Gastroenterol J 2013; 1: A1.
66. Scott FI, Lichtenstein GR. Therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. Curr Treat Options Gastroenterol 2014; 12: 59-75. http://dx.doi.org/10.1007/s11938-013-0004-5
67. Vande Casteele N, Buurman DJ, Sturkenboom MG, Kleibeuker JH, Vermeire S, Rispens T, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012; 36: 765-71. http://dx.doi.org/10.1111/apt.12030
68. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. BMJ 2009; 339: b2535. http://dx.doi.org/10.1136/bmj.b2535
69. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529-36. http://dx.doi.org/10.7326/0003-4819-155-8-201110180-00009
70. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928. http://dx.doi.org/10.1136/bmj.d5928
71. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998; 52: 377-84. http://dx.doi.org/10.1136/jech.52.6.377
72. Chang SM, Matchar DB, Smetana GW, Umscheid CA, Gray R, Torchia MM. Methods Guide for Medical Test Reviews. Agency for Healthcare Research and Quality (AHRQ) publication no. 12-EC017. Rockville, MD: AHRQ; 2012. URL: www.effectivehealthcare.ahrq.gov/ehc/products/246/558/Methods-Guide-for-Medical-Test-Reviews_Full-Guide_20120530.pdf (accessed 11 March 2015).
73. Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015; 148: 1320-9.e3. http://dx.doi.org/10.1053/j.gastro.2015.02.031
74. Guyot P, Ades A, Ouwens M, Welton N. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 2012; 12: 9. http://dx.doi.org/10.1186/1471-2288-12-9
75. Harbord R, Whiting P. metandi: meta-analysis of diagnostic accuracy using hierarchical logistic regression. Stata J 2009; 9: 211-29.
76. Harris RJ, Bradburn MJ, Deeks JJ, Harbord R, Altman DG, Sterne JAC. Metan: fixed- and random-effects meta-analysis. Stata J 2008; 8: 3-28.
77. Baert F, Drobne D, Gils A, Vande Casteele N, Hauenstein S, Singh S, et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol 2014; 12: 1474-81.e2. http://dx.doi.org/10.1016/j.cgh.2014.01.033
78. Ben-Bassat O, Romanova A, Iacono A, Irwin SP, Greenberg GR. Association of serum infliximab and antibodies to infliximab to long-term clinical outcome and mucosal healing in Crohn’s disease. Gastroenterology 2013; 144: S-775. http://dx.doi.org/10.1016/S0016-5085(13)62866-8
79. Ben-Horin S, Yavzori M, Katz L, Kopylov U, Picard O, Fudim E, et al. The immunogenic part of infliximab is the F(ab’)2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011; 60: 41-8. http://dx.doi.org/10.1136/gut.2009.201533
80. Ben-Horin S, Mazor Y, Yanai H, Ron Y, Kopylov U, Yavzori M, et al. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. Aliment Pharmacol Ther 2012; 35: 714-22. http://dx.doi.org/10.1111/j.1365-2036.2012.04997.x
81. Bodini G, Savarino V, Dulbecco P, Baldissarro I, Savarino E. ELISA vs. HMSA: a comparison between two different methods for the evaluation of adalimumab serum concentration and anti-adalimumab antibodies preliminary data. J Crohns Colitis 2014; 8: S278. http://dx.doi.org/10.1016/S1873-9946(14)60625-5
82. Bortlik M, Duricova D, Malickova K, Machkova N, Bouzkova E, Hrdlicka L, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn’s disease. J Crohns Colitis 2013; 7: 736-43. http://dx.doi.org/10.1016/j.crohns.2012.10.019
83. Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cezard JP. Clinical and biological consequences of immunization to infliximab in pediatric Crohn’s disease. Clin Immunol 2006; 118: 11-19. http://dx.doi.org/10.1016/j.clim.2005.07.010
84. Chiu YL, Rubin DT, Vermeire S, Louis E, Robinson AM, Lomax KG, et al. Serum adalimumab concentration and clinical remission in patients with Crohn’s disease. Inflamm Bowel Dis 2013; 19: 1112-22. http://dx.doi.org/10.1097/MIB.0b013e3182813242
85. Cornillie F, Hanauer SB, Diamond RH, Wang J, Tang KL, Xu Z, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014; 63: 1721-7. http://dx.doi.org/10.1136/gutjnl-2012-304094
86. Corstjens PL, Fidder HH, Wiesmeijer KC, de Dood CJ, Rispens T, Wolbink GJ, et al. A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study. Anal Bioanal Chem 2013; 405: 7367-75. http://dx.doi.org/10.1007/s00216-013-7154-0
87. Daperno M, Frigerio F, Guiotto C, Germano L, Ercole E, Arico S, et al. Evaluation of the diagnostic performance of two commercially available tests for infliximab trough levels (IFX-TL) and antibodies to infliximab (ATI) titration in inflammatory bowel disease (IBD). J Crohns Colitis 2013; 7: S213-14. http://dx.doi.org/10.1016/S1873-9946(13)60529-2
88. Dauer RM, Yarur AJ, Abreu MT. Infliximab re-induction outcomes after a failure to treatment. Gastroenterol 2013; 144: S-430. http://dx.doi.org/10.1016/S0016-5085(13)61583-8
89. Egea-Pujol L, Reddy R, Patel S, Christie R, Salbato J, Shah S, et al. Homogenous mobility shift assay (HMSA) overcomes the limitations of ELISA and ECLIA assays for monitoring infliximab (IFX), adalimumab (ADA), and associated anti-drug antibodies in serum. Am J Gastroenterol 2013; 108: S548.
90. Eser A, Primas C, Hauenstein S, Lockton S, Singh S, Reinisch W. Comparison of early measurement of infliximab and antibodies-to-infliximab serum levels with standard trough analysis. Gastroenterology 2013; 144: S-779. http://dx.doi.org/10.1016/S0016-5085(13)62880-2
91. Eser A, Primas C, Haunstein S, Lockton S, Wang S, Singh S, et al. Detection of anti infliximab antibodies in patients with inflammatory bowel disease (IBD) in the presence of infliximab by homogeneous liquid phase anti infliximab mobility shift assay. J Crohns Colitis 2013; 7: S231-2. http://dx.doi.org/10.1016/S1873-9946(13)60572-3
92. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-24. http://dx.doi.org/10.1053/gast.2003.50145
93. Feagan BG, Singh S, Lockton S, Hauenstein S, Ohrmund L, Croner LJ, et al. Novel infliximab (IFX) and antibody-to-infliximab (ATI) assays are predictive of disease activity in patients with Crohn’s disease (CD). Gastroenterology 2012; 142: S-114. http://dx.doi.org/10.1016/S0016-5085(12)60430-2
94. Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K, Steenholdt C. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Inflamm Bowel Dis 2014; 20: 1714-21. http://dx.doi.org/10.1097/MIB.0000000000000138
95. Goldberg R, Beswick L, Van Langenberg D, Sally B, Rosella O, Gibson P, et al. Predictors of sub-therapeutic infliximab or adalimumab trough levels and anti-drug antibodies and their influence on therapeutic decisions. J Crohns Colitis 2014; 5: S223. http://dx.doi.org/10.1016/S1873-9946(14)60498-0
96. Greathead L, Kelleher P, Steel A. Development and validation of ELISA to measure serum anti TNFa levels. J Crohns Colitis 2014; 8: S97-8. http://dx.doi.org/10.1016/S1873-9946(14)60208-7
97. Hauenstein S, Ohrmund L, Salbato J, Reddy R, McCowen K, Monk P, et al. Comparison of homogeneous mobility shift assay and solid phase elisa for the measurement of drug and anti-drug antibody (ADA) levels in serum from patients treated with anti-TNF biologics. Gastroenterology 2012; 142: S-538. http://dx.doi.org/10.1016/S0016-5085(12)62067-8
98. Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Sato N, et al. C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease. J Gastroenterol 2014; 49: 254-62. http://dx.doi.org/10.1007/s00535-013-0807-0
99. Imaeda H, Andoh A, Fujiyama Y. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. J Gastroenterol 2012; 47: 136-43. http://dx.doi.org/10.1007/s00535-011-0474-y
100. Imaeda H, Takahashi K, Fujimoto T, Bamba S, Tsujikawa T, Sasaki M, et al. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s disease. J Gastroenterol 2014; 49: 100-9. http://dx.doi.org/10.1007/s00535-013-0803-4
101. Imaeda H, Bamba S, Takahashi K, Fujimoto T, Ban H, Tsujikawa T, et al. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn’s disease under scheduled maintenance treatment. J Gastroenterol 2014; 49: 674-82. http://dx.doi.org/10.1007/s00535-013-0829-7
102. Kong JY, Bundell CS, Pawlik J, Hollingsworth PN, Forbes GM. Trough serum infliximab level, anti-infliximab antibody status and response to infliximab maintenance treatment in inflammatory bowel disease (IBD). J Gastroenterol Hepatol 2011; 26: 59-60.
103. Kopylov U, Mazor Y, Yavzori M, Fudim E, Katz L, Coscas D, et al. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis 2012; 18: 1628-33. http://dx.doi.org/10.1002/ibd.21919
104. Levesque BG, Greenberg GR, Zou G, Sandborn WJ, Singh S, Hauenstein S, et al. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn’s disease. Aliment Pharmacol Ther 2014; 39: 1126-35. http://dx.doi.org/10.1111/apt.12733
105. Marits P, Landucci L, Sundin U, Davidsdottir L, Nilsson J, Befrits R, et al. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment. J Crohns Colitis 2014; 8: 881-9. http://dx.doi.org/10.1016/j.crohns.2014.01.009
106. Marzo M, Armuzzi A, Felice C, Pugliese D, Andrisani G, Tolusso B, et al. Role of trough levels and antibodies to infliximab in the evaluation of loss of response and infusion reactions to infliximab therapy in inflammatory bowel disease. Dig Liver Dis 2014; 46: S77. http://dx.doi.org/10.1016/S1590-8658(14)60224-3
107. Mazor Y, Kopylov U, Hur DB, Almog R, Waterman M, Ben-Horin S, et al. Evaluating adalimumab drug and antibody levels as predictors of clinical and laboratory response in Crohn’s disease patients. Gastroenterology 2013; 144: S-778. http://dx.doi.org/10.1016/S0016-5085(13)62874-7
108. Mazor Y, Almog R, Kopylov U, Ben Hur D, Blatt A, Dahan A, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn’s disease. Aliment Pharmacol Ther 2014; 40: 620-8. http://dx.doi.org/10.1111/apt.12869
109. McTigue M, Sandborn W, Levesque B, Patel D. Clinical utility of next generation infliximab and antibodies to infliximab assay. Am J Gastroenterol 2013; 108: S527.
110. Nagore D, Ruiz Del Agua A, Pascual J, Llinares-Tello F, Herreros B, Martinez A. Therapeutic cut-off of infliximab in patients with inflammatory bowel diseases. Gut 2015; 64: A99. http://dx.doi.org/10.1136/gutjnl-2015-309861.202
111. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013; 108: 40-7. http://dx.doi.org/10.1038/ajg.2012.363
112. Pallagi-Kunstar E, Farkas K, Szepes Z, Nagy F, Szucs M, Kui R, et al. Utility of serum TNF-alpha, infliximab trough level, and antibody titers in inflammatory bowel disease. World J Gastroenterol 2014; 20: 5031-5. http://dx.doi.org/10.3748/wjg.v20.i17.5031
113. Paul S, Tedesco ED, Marotte H, Phelip JM, Genin C, Roblin X. Interest of the dosage of serum concentration of infliximab and antibodies anti infliximab in the therapeutic response under infliximab in IBD. Gastroenterology 2012; 142: S354. http://dx.doi.org/10.1016/S0016-5085(12)61332-8
114. Paul S, Moreau AC, Del Tedesco E, Rinaudo M, Phelip JM, Genin C, et al. Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm Bowel Dis 2014; 20: 1288-95. http://dx.doi.org/10.1097/MIB.0000000000000037
115. Roblin X, Marotte H, Rinaudo M, Del Tedesco E, Moreau A, Phelip JM, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014; 12: 80-4.e2. http://dx.doi.org/10.1016/j.cgh.2013.07.010
116. Ruiz-Arguello B, del Agua AR, Torres N, Monasterio A, Martinez A, Nagore D. Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med 2013; 51: e287-9. http://dx.doi.org/10.1515/cclm-2013-0461
117. Schatz SB, Prell C, Freudenberg F, Hajji M, Bufler P, Koletzko S. PA-G-0035 Comparison of different tests for determination of infliximab levels and antibodies against infliximab in pediatric IBD patients. The 46th Annual Meeting of The European Society of Paediatric Gastroenterology, Hepatology and Nutrition, London, 8-11 May 2013. J Pediatr Gastroenterol Nutr 2013; 56: 19.
118. Semmler J, Pilch A, Armbruster F, Dignass A, Stein J. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. Clin Chem Lab Med 2013; 51: eA27-8.
119. Singh N, Rosenthal CJ, Melmed GY, Mirocha J, Farrior S, Callejas S, et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2014; 20: 1708-13. http://dx.doi.org/10.1097/MIB.0000000000000137
120. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn’s disease. Scand J Gastroenterol 2011; 46: 310-18. http://dx.doi.org/10.3109/00365521.2010.536254
121. Steenholdt C, Ainsworth MA, Tovey M, Klausen TW, Thomsen OO, Brynskov J, et al. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn’s disease. Ther Drug Monit 2013; 35: 530-8. http://dx.doi.org/10.1097/FTD.0b013e31828d23c3
122. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn’s disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol 2014; 109: 1055-64. http://dx.doi.org/10.1038/ajg.2014.106
123. Steenholdt C, Brynskov J, Thomsen OO, Munck LK, Fallingborg J, Christensen LA, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014; 63: 919-27. http://dx.doi.org/10.1136/gutjnl-2013-305279
124. Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, et al. Individualized therapy is a long-term cost-effective method compared to dose intensification in Crohn’s disease patients failing infliximab. Dig Dis Sci 2015; 60: 2762-70. http://dx.doi.org/10.1007/s10620-015-3581-4
125. Ungar B, Anafy A, Kopylov U, Ron Y, Yanai H, Dotan I, et al. The clinical and immunological significance of low level of infliximab in the absence of anti-infliximab antibodies in patients with IBD. Gastroenterology 2014; 146: S-245. http://dx.doi.org/10.1016/S0016-5085(14)60862-3
126. Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013; 108: 962-71. http://dx.doi.org/10.1038/ajg.2013.12
127. Vande Casteele N, Peeters M, Compernolle G, Ferrante M, Van Assche GA, Vermeire S, et al. TNF-responsive cellular based assay reveals neutralizing capacity of anti-adalimumab antibodies in Crohn’s disease and ulcerative colitis patients. Gastroenterology 2014; 146: S-242. http://dx.doi.org/10.1016/S0016-5085(14)60852-0
128. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis 2014; 20: 1996-2003. http://dx.doi.org/10.1097/MIB.0000000000000156
129. Wang SL, Ohrmund L, Singh S. Measurement of human anti-chimeric antibodies (HACA) and infliximab levels in patient serum using a novel homogeneous assay. Gastroenterology 2010; 138: S684-5. http://dx.doi.org/10.1016/s0016-5085(10)63147-2
130. Wang SL, Ohrmund L, Hauenstein S, Salbato J, Reddy R, Monk P, et al. Evaluation of a novel homogeneous mobility shift assay for the measurement of human antibodies-to-infliximab and infliximab levels in patient serum. Am J Gastroenterol 2011; 106: S475-6.
131. Wang SL, Ohrmund L, Hauenstein S, Salbato J, Reddy R, Monk P, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-toinfliximab levels in patient serum. J Immunol Methods 2012; 382: 177-88. http://dx.doi.org/10.1016/j.jim.2012.06.002
132. Ward MG, Kariyawasam VC, Mogan SB, Blaker PA, Patel KP, Pantelidou M, et al. Clinical utility of measuring adalimumab trough levels and antibodies to adalimumab in patients with inflammatory bowel diseases. J Gastroenterol Hepatol 2013; 28: 100-1.
133. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease. Aliment Pharmacol Ther 2008; 28: 1122-6. http://dx.doi.org/10.1111/j.1365-2036.2008.03828.x
134. Yanai H, Mlynarsky L, Ron Y, Ben Yehoyada M, Yeshuron D, Santo EM, et al. The questionable value of infliximab trough levels during prolonged maintenance therapy. Gastroenterology 2012; 142: S788-9. http://dx.doi.org/10.1016/S0016-5085(12)63061-3
135. Yarur AJ, Deshpande AR, Sussman DA, Hauenstein S, Lockton S, Barkin JS, et al. TU1147 serum adalimumab levels and antibodies correlate with endoscopic intestinal inflammation and inflammatory markers in patients with inflammatory bowel disease. Gastroenterology 2013; 144: S774-5. http://dx.doi.org/10.1016/S0016-5085(13)62863-2
136. Rispens T, van der Kleij D. Reply to Ruiz-Arguello et al.: comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med 2013; 51: e291-2. http://dx.doi.org/10.1515/cclm-2013-0570
137. Garces S, Demengeot J, Benito-Garcia E. Clinical impact of immunogenicity of infliximab, adalimumab and etanercept: a systematic review of the literature with a meta-analysis (SAT0479). Ann Rheum Dis 2013; 71: 634-5. http://dx.doi.org/10.1136/annrheumdis-2012-eular.3425
138. Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Therap Adv Gastroenterol 2013; 6: 269-93. http://dx.doi.org/10.1177/1756283X13479826
139. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011; 106: 685-98. http://dx.doi.org/10.1038/ajg.2011.103
140. Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease. Gut 2014; 64: 1539-45. http://dx.doi.org/10.1136/gutjnl-2014-307883
141. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011. URL: www.cochrane-handbook.org (accessed 15 January 2015).
142. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54. http://dx.doi.org/10.1136/gut.2009.183095
143. Pepe NS. The Statistical Evaluation of Medical Tests for Classification and Prediction. New York, NY: Oxford University Press; 2003.
144. Harbord RM, Deeks JJ, Egger M, Whiting P, Sterne JA. A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics 2007; 8: 239-51. http://dx.doi.org/10.1093/biostatistics/kxl004
145. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl JMed 2005; 353: 2462-76. http://dx.doi.org/10.1056/NEJMoa050516
146. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350: 876-85. http://dx.doi.org/10.1056/NEJMoa030815
147. Miele E, Markowitz JE, Mamula P, Baldassano RN. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 2004; 38: 502-8. http://dx.doi.org/10.1097/00005176-200405000-00008
148. Steenholdt C, Svenson M, Bendtzen K, Thomsen O, Brynskov J, Ainsworth MA. Can measurements of anti-infliximab antibodies predict acute severe infusion reactions to infliximab? Gastroenterology 2011; 140: S774.
149. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8(36). http://dx.doi.org/10.3310/hta8360
150. Silverstein MD, Loftus EV, Sandborn WJ, Tremaine WJ, Feagan BG, Nietert PJ, et al. Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterology 1999; 117: 49-57. http://dx.doi.org/10.1016/S0016-5085(99)70549-4
151. Joint Formulary Committee. British National Formulary. 53 ed. London: BMJ Group and Pharmaceutical Press; 2007.
152. Joint Formulary Committee. British National Formulary. 55 ed. London: BMJ Group and Pharmaceutical Press; 2008.
153. Department of Health. NHS Reference Costs 2005 to 2006. London: Department of Health; 2006.
154. Blackhouse G, Assasi N, Xie F, Marshall J, Irvine EJ, Gaebel K, et al. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-alpha drugs for refractory Crohn’s disease. J Crohns Colitis 2012; 6: 77-85. http://dx.doi.org/10.1016/j.crohns.2011.07.007
155. Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther 2009; 30: 265-74. http://dx.doi.org/10.1111/j.1365-2036.2009.04033.x
156. Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007; 26: 1509-20. http://dx.doi.org/10.1111/j.1365-2036.2007.03548.x
157. Velayos FS, Kahn JG, Sandborn WJ, Feagan BG. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn’s disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol 2013; 11: 654-66. http://dx.doi.org/10.1016/j.cgh.2012.12.035
158. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Technol Assess Health Care 2013; 29: 117-22. http://dx.doi.org/10.1017/S0266462313000160
159. Juillerat P, Sokol H, Froehlich F, Yajnik V, Beaugerie L, Lucci M, et al. Factors associated with durable response to infliximab in Crohn’s disease 5 years and beyond: a multicenter international cohort. Inflamm Bowel Dis 2015; 21: 60-70. http://dx.doi.org/10.1097/MIB.0000000000000225
160. van der Have M, van der Aalst KS, Kaptein AA, Leenders M, Siersema PD, Oldenburg B, et al. Determinants of health-related quality of life in Crohn’s disease: a systematic review and meta-analysis. J Crohns Colitis 2014; 8: 93-106. http://dx.doi.org/10.1016/j.crohns.2013.04.007
161. Ma C, Huang V, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, et al. Crohn’s disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study. J Crohns Colitis 2014; 8: 1454-63. http://dx.doi.org/10.1016/j.crohns.2014.05.007
162. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-38. http://dx.doi.org/10.7326/0003-4819-146-12-200706190-00159
163. Nguyen GC, Nugent Z, Shaw S, Bernstein CN. Outcomes of patients with Crohn’s disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology 2011; 141: 90-7. http://dx.doi.org/10.1053/j.gastro.2011.03.050
164. Gordon M, Taylor K, Akobeng AK, Thomas AG. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease. Cochrane Database Syst Rev 2014; 8: CD010233. http://dx.doi.org/10.1002/14651858.cd010233.pub2
165. Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999; 117: 761-9. http://dx.doi.org/10.1016/S0016-5085(99)70332-X
166. Joint Formulary Committee. British National Formulary. 66 ed. London: BMJ Group and Pharmaceutical Press; 2013.
167. Department of Health. NHS Reference Costs 2013 to 2014. London: Department of Health; 2014. URL: www.gov.uk/government/publications/nhs-reference-costs-2013-to-2014 (accessed 24 March 2015).
168. Marchetti M, Liberato NL. Biological therapies in Crohn’s disease: are they cost-effective? A critical appraisal of model-based analyses. Expert Rev Pharmacoecon Outcomes Res 2014; 14: 815-24. http://dx.doi.org/10.1586/14737167.2014.957682
169. Office for National Statistics. National Life Tables, United Kingdom, 1980-82 to 2011-13. 2014. URL: www.ons.gov.uk/ons/search/index.html?newquery=National+Life+Tables%2C+United +Kingdom%2C+1980-82+to+2011-13 (accessed 31 March 2015).
170. Curtis L. Unit Costs of Health and Social Care 2014. Canterbury: Personal Social Services Research Unit, University of Kent; 2014. URL: www.pssru.ac.uk/project-pages/unit-costs/2014/ (accessed 24 March 2015).
171. Saito S, Shimizu U, Zhang N, Yokoyama J, Watanabe M, Terajima K, et al. A health economic analysis of combination therapy with infliximab plus elemental diet for moderately to severely active Crohn’s disease. Health (NY) 2014; 6: 107-14. http://dx.doi.org/10.4236/health.2014.61017
172. Rai T, Navaneethan U, Dalal D, Lashner B, Shen B. Clinical implications of measuring infliximab levels and human anti-chimeric antibodies in patients with inflammatory bowel disease. Am J Gastroenterol 2012; 107: S634.
173. Armbruster S, Ally M, Maydonovitch C, Betteridge J, Veerappan G. The use of human anti-chimeric antibody (HACA) and infliximab levels in the management of inflammatory bowel disease. Am J Gastroenterol 2012; 107: S641.
174. Vande Casteele N, Drake K, Hauenstein S, Levesque BG, Singh S, Sandborn W. Infliximab and antibody to infliximab concentrations in 7,613 patients shows indication for testing, association with loss of response and provides new insights into binding characteristics of anti-drug antibodies. Gastroenterology 2014; 146: S-242. http://dx.doi.org/10.1016/S0016-5085(14)60853-2
175. Wolf DC, Lockton S, Hauenstein S, Carroll S, Singh S, Chuang E. A multi-center observational study in community gastroenterology practices evaluating the clinical usage of testing for serum levels of infliximab and antibodies to infliximab. Gastroenterology 2013; 144: S-423. http://dx.doi.org/10.1016/S0016-5085(13)61559-0
176. Turon J, Langseder A, Irizarry R, Ahuja K, Rosh JR. Clinical outcome of pediatric IBD patients after measurement of infliximab drug and anti-drug antibody levels. Gastroenterology 2013; 144: S531. http://dx.doi.org/10.1016/S0016-5085(13)61975-7
177. Turvill J. Mapping of Crohn’s disease outcomes to faecal calprotectin levels in patients maintained on biologic therapy. Frontline Gastroenterol 2014; 5: 167-75. http://dx.doi.org/10.1136/flgastro-2014-100441
178. NICE. Infliximab, Adalimumab and Golimumab for Treating Moderately to Severely Active Ulcerative Colitis after the Failure of Conventional Therapy. NICE technology appraisal guidance [TA329]. London: NICE; 2015.
179. Bar-yoseph H, Chowers Y, Ben-Horin S, Waterman M. Infliximab is more immunogenic and reaches lower trough levels in ulcerative colitis patients compared to Crohn’s disease patients. Gastroenterology 2013; 144: S-780. http://dx.doi.org/10.1016/S0016-5085(13)62883-8
180. D’Haens GR, Vermiere S, Lambrecht G, Baert FJ, Bassuyt P, Nachury M, et al. 692 Drug-level based dosing versus symptom-based dose adaptation in patients with crohn’s disease: a prospective, randomized multicenter study (TAILORIX). Gastroenterology 2016; 150: S143. http://dx.doi.org/10.1016/S0016-5085(16)30583-2
181. D’Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Nachury M, et al. OP029 Drug-Concentration Versus Symptom-Driven Dose Adaptation of Infliximab in Patients with Active Crohn’s Disease: A Prospective, Randomised, Multicentre Trial (Tailorix). European Crohn’s and Colitis Organisation; 2016. URL: www.ecco-ibd.eu/index.php/publications/congress-abstract-s/abstracts-2016/item/op029-drug-concentration-versus-symptom-driven-dose-adaptation-ofinfliximab-in-patients-with-active-crohnix2019is-disease-a-prospective-randomised-multicentretrial-tailorix.html (accessed 29 September 2016).
182. Nagore D, Ruiz Del Agua A, Pascual J, Llinares-Tello F, Herreros B, Martinez A. TU1325 therapeutic cut-off of infliximab in patients with inflammatory bowel diseases. Gastroenterology 2015; 148: S-860. http://dx.doi.org/10.1016/S0016-5085(15)32913-9
183. Vester-Andersen MK, Vind I, Prosberg MV, Bengtsson BG, Blixt T, Munkholm P, et al. Hospitalisation, surgical and medical recurrence rates in inflammatory bowel disease 2003-2011 -a Danish population-based cohort study. J Crohns Colitis 2014; 8: 1675-83. http://dx.doi.org/10.1016/j.crohns.2014.07.010
184. Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB. Natural history of Crohn’s disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010; 59: 1200-6. http://dx.doi.org/10.1136/gut.2009.202101
185. Armuzzi A, Felice C, Papa A, Marzo M, Pugliese D, Andrisani G, et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn’s disease: an open-label pilot study. J Crohns Colitis 2013; 7: e623-9. http://dx.doi.org/10.1016/j.crohns.2013.04.020